Parse Biosciences Launches Evercode Whole Transcriptome V4 With Shorter Workflow, Higher Sensitivity and Higher Cell Recovery
MWN-AI** Summary
Parse Biosciences, a subsidiary of QIAGEN, is poised to revolutionize single-cell RNA sequencing with the launch of the Evercode™ Whole Transcriptome V4 product line, scheduled for release in March 2026. This innovative offering marks a significant advancement in single-cell sequencing technology, featuring improved scalability, heightened sensitivity, and a more efficient workflow.
The Evercode V4 supports an impressive capacity of up to five million cells and 384 samples per run, enabling researchers to conduct large-scale studies without sacrificing sample accuracy. Enhanced chemistry boosts the detection of genes per cell while minimizing the number of required sequencing reads, leading to substantial cost reductions in sequencing.
A pivotal change in the workflow is the introduction of a magnetic bead-based method that replaces traditional centrifugation, resulting in a remarkable 75% increase in cell recovery rates. This enhancement allows researchers to extract valuable data from limited or precious samples, streamlining the process by reducing hands-on time and the number of pipetting steps. Additionally, Evercode V4 is compatible with laboratory automation, making it accessible even for those with limited single-cell experience.
The product also promises to eliminate off-target reads, ensuring higher gene detection per cell, even at lower sequencing depths and costs. This higher sensitivity is crucial for studies focusing on rare cell types or genes that are expressed at low levels.
Reflecting on the development, Dr. Charlie Roco, Co-founder and Chief Technology Officer of Parse Biosciences, highlighted that the Evercode V4 embodies years of customer feedback and innovation aimed at enhancing single-cell technology accessibility and performance.
Researchers can expect to learn more at the upcoming AGBT meeting and through a webinar set for March 3, 2026. For more updates, visit Parse Biosciences' website.
MWN-AI** Analysis
Parse Biosciences, a QIAGEN subsidiary, is set to launch its Evercode Whole Transcriptome v4 product line in March 2026, which presents investors with an opportunity to assess the potential impact on the single-cell sequencing market. This enhanced version addresses key barriers by providing a more sensitive and scalable solution, encouraging widespread usage in various research settings.
With the ability to process up to five million cells and 384 samples in a single run, the Evercode v4's expanded scalability positions it to meet the growing demand for large-scale biological studies. This shift is particularly relevant amid increasing funding in life sciences aimed at understanding complex biological systems, thus enhancing growth prospects for Parse Biosciences.
The introduction of a magnetic bead-based workflow, which boosts cell recovery by up to 75%, coupled with a reduction in sequencing needs, can lower operational costs significantly. For researchers operating with limited or precious samples, this could generate increased demand for Evercode v4, translating into potential revenue growth for Parse and its parent company, QIAGEN.
Additionally, with enhanced gene detection capabilities at lower sequencing depths, the product can cater to niche research areas focused on rare cell types and lowly expressed genes. This unique value proposition can serve as a competitive differentiator in the crowded genomic analysis market.
However, while these advancements are promising, investors should remain cognizant of potential challenges, including regulatory hurdles and market competition. As results from initial customer feedback and large-scale studies come in leading up to the 2026 launch, those involved in the life sciences sector should closely monitor Parse Biosciences' progress and competitor responses, which will shape market dynamics in the single-cell sequencing field. Overall, Parse's strategic innovations position it as a noteworthy player in a domain ripe for expansion.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- New chemistry reduces barriers to scaling single-cell studies across research settings
- Launch planned for March 2026, available across Evercode Whole Transcriptome product line
Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing.
Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers to design large studies while maintaining sample resolution. The upgraded chemistry increases gene detection per cell while requiring fewer sequencing reads, helping reduce overall sequencing costs.
A new magnetic bead-based workflow replaces centrifugation steps and increases cell recovery by up to 75%, allowing researchers to generate more data from limited or precious samples. The streamlined process reduces hands-on time and pipetting steps and is designed to support laboratory automation, making the system accessible to laboratories with varying levels of single-cell experience.
Additionally, Evercode v4 eliminates off-target reads, enabling higher gene detection per cell even at lower sequencing depths and lower costs than other solutions. With higher sensitivity, Evercode v4 delivers higher biological resolution for researchers studying rare cell types or lowly expressed genes.
Evercode Whole Transcriptome v4 chemistry is available across the Evercode Whole Transcriptome product line, including Evercode Fixation and experiments processed through Parse’s GigaLab.
“Our goal from the beginning was to provide the research community with single cell technology that is scalable, accessible, and high-performing,” said Charlie Roco, PhD, Co-founder and Chief Technology Officer of Parse Biosciences. “Evercode v4 reflects years of work and direct feedback from customers, delivering a leap forward in cell recovery and sensitivity combined with a simpler workflow.”
Evercode Whole Transcriptome v4 is planned to begin shipping in March 2026.
To learn more about the new chemistry, visit Parse at the upcoming AGBT meeting (Duval Room) or register for Parse’s upcoming webinar on Tuesday, March 3, 2026 at 9:00 AM Pacific:
https://resources.parsebiosciences.com/evercode-wt-v4 .
About Parse Biosciences
Parse Biosciences, a QIAGEN Company, is a global life sciences leader whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach has enabled groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development and the immune system. For more information, visit www.parsebiosciences.com .
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and Molecular Diagnostics (clinical healthcare). As of December 31, QIAGEN employed approximately 5,700 people across more than 35 locations. For more information, visit www.qiagen.com .
Forward-Looking Statement
Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN’s products, development timelines, marketing and/or regulatory approvals, financial and operational outlook, growth strategies, capital allocation strategies, collaborations and operating results (such as expected net sales and adjusted diluted earnings), the CEO transition plan, the acquisition of Parse Biosciences, including the timing and expected benefits thereof, and the synthetic share repurchase, including the timing and expected benefits thereof, are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to: challenges in managing a successful CEO transition and successor search while providing operational continuity and continued advancement of company strategy; challenges in managing growth and international operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistical dependencies); variability in operating results and the commercial development of products for customers in the Life Sciences and clinical healthcare markets; changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancement; developments or changes in the securities markets and fluctuations in the trading volume and market price of QIAGEN’s shares and the successful implementation of the synthetic share repurchase; QIAGEN’s ability to successfully close, integrate and achieve the expected benefits of its acquisition of Parse Biosciences, including fluctuating demand for QIAGEN’s products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional risks and uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other “force majeure” events. There is also no guarantee that anticipated benefits from restructuring programs and acquisitions will materialize as expected. For a more complete discussion of risks and uncertainties, please refer to the “Risk Factors” section in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission.
Source: QIAGEN N.V.
Category: Life Sciences
View source version on businesswire.com: https://www.businesswire.com/news/home/20260219752156/en/
Parse contact:
Kaitie VanDenHeuvel-Kramer
kkramer@parsebiosciences.com
+1 858-504-0455
QIAGEN contacts:
Public Relations
e-mail: pr@QIAGEN.com
Investor Relations
e-mail: ir@QIAGEN.com
FAQ**
How does the launch of Parse Biosciences' Evercode Whole Transcriptome v4 align with Qiagen N.V. QGEN’s strategic goals in the life sciences sector?
What specific market demands or trends led to the development of the Evercode v4 product line by Parse Biosciences, a QIAGEN company (NYSE: QGEN)?
How does the increased cell recovery achieved by the new Evercode chemistry benefit Qiagen N.V. QGEN in terms of cost-effectiveness and competitive advantage?
What measures is Qiagen N.V. QGEN putting in place to address potential risks associated with the rollout of the Evercode Whole Transcriptome vparticularly concerning regulatory approvals?
**MWN-AI FAQ is based on asking OpenAI questions about Qiagen N.V. (NYSE: QGEN).
NASDAQ: QGEN
QGEN Trading
1.58% G/L:
$41.16 Last:
892,000 Volume:
$41.83 Open:
